Flexible Lithium Battery for Wearable Electronics by Columbia Engineers

January 31, 2018 Scipreneur Private Limited 0

Flexible Lithium Battery for Wearable Electronics by Columbia Engineers By: Columbia University School of Engineering and Applied Science The rapid development of flexible and wearable electronics is giving rise to an exciting range of applications, from smart watches and flexible displays—such as smart phones, tablets, and TV—to smart fabrics, smart glass, transdermal [..]

FDA Approved Lutathera® of Novartis for Treatment of Gastroenteropancreatic Neuroendocrine Tumors

January 26, 2018 Scipreneur Private Limited 0

FDA Approved Lutathera® of Novartis for Treatment of Gastroenteropancreatic Neuroendocrine Tumors By: Novartis Media Release Novartis AG (NYSE: NVS) today announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approval of its new drug application (NDA) for Lutathera® (lutetium Lu 177 dotatate*) [..]

Daily Routine of Successful People

January 25, 2018 Scipreneur Private Limited 0

Daily Routine of Successful People By: Vijay Soni, Ph.D. | Founder and C.E.O. Scipreneur “The secret of your future is hidden in your daily routine.” — Mike Murdock The daily routine of a successful person has the same habits day in and day out. It won’t be easy to make the changes, all you [..]

Let’s Start a Startup!

January 25, 2018 Scipreneur Private Limited 0

Let’s Start a Startup! By: Vijay Soni, Ph.D. | Founder and C.E.O. Scipreneur “A startup is a temporary organization used to search for a repeatable and scalable business model” –  Steve Blank Setting up a startup is not easy. But if you have an idea that you think deserves to be shared, if you think that you [..]

Novartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for patients with rare inherited vision loss

January 25, 2018 Scipreneur Private Limited 0

Novartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for patients with rare inherited vision loss By: Novartis Media Release Novartis today announced a licensing agreement with Spark Therapeutics covering development, registration and commercialization rights to voretigene neparvovec in markets outside the US. Voretigene neparvovec, [..]

Supercharged Antibiotics Could Turn Tide Against Superbugs

January 7, 2018 Scipreneur Private Limited 0

Supercharged Antibiotics Could Turn Tide Against Superbugs By: University of Queensland News An old drug supercharged by University of Queensland researchers has emerged as a new antibiotic that could destroy some of the world’s most dangerous superbugs. The supercharge technique , led by Dr Mark Blaskovich and Professor Matt Cooper from UQ’s Institute for [..]

First Step Toward Cell-Sized Robots

January 7, 2018 Scipreneur Private Limited 0

First Step Toward Cell-Sized Robots By: Tom Fleischman,  Cornell Chronicle  An electricity-conducting, environment-sensing, shape-changing machine the size of a human cell? Is that even possible? Cornell physicists Paul McEuen and Itai Cohen not only say yes, but they’ve actually built the “muscle” for one. With postdoctoral researcher Marc Miskinat the helm, the team has made [..]

FDA Granted Breakthrough Therapy Designation to Novartis Kisqali®

January 7, 2018 Scipreneur Private Limited 0

FDA Granted Breakthrough Therapy Designation to Novartis Kisqali® By: Novartis News Novartis announced Kisqali® (ribociclib) received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pre- or perimenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in combination with [..]

Promacta® of Novartis Receives FDA Breakthrough Therapy Designation for First-Line Use in Severe Aplastic Anemia (SAA)

January 7, 2018 Scipreneur Private Limited 0

Promacta® of Novartis Receives FDA Breakthrough Therapy Designation for First-Line Use in Severe Aplastic Anemia (SAA) Novartis today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Promacta®(eltrombopag) for use in combination with standard immunosuppressive therapy for the treatment of patients with severe aplastic [..]

World Business Forum; Sydney

January 4, 2018 Scipreneur Private Limited 0

World Business Forum Sydney, May 30-31, 2018; Price TBA Come hear an amazing group of inspirational speakers who are paving their own way and challenging traditions in business. You’ll be inspired by fresh ideas, start rethinking the status quo, and leave ready to tackle your own business challenges in creative and [..]

Four-dimensional Physics in Two Dimensions

January 4, 2018 Scipreneur Private Limited 0

Four-dimensional Physics in Two Dimensions By:  Penn State News For the first time, physicists have built a two-dimensional experimental system that allows them to study the physical properties of materials that were theorized to exist only in four-dimensional space. An international team of researchers from Penn State, ETH Zurich in Switzerland, [..]

Flexible, Stretchable, and Low-Cost Electronics by Metal Printing

January 4, 2018 Scipreneur Private Limited 0

Flexible, Stretchable, and Low-Cost Electronics by Metal Printing By: North Carolina State University News Researchers from North Carolina State University have developed a new technique for directly printing metal circuits, creating flexible, stretchable electronics. The technique can use multiple metals and substrates and is compatible with existing manufacturing systems that employ direct printing [..]

Diabetes drug “significantly reverses memory loss” in mice with Alzheimer’s

January 4, 2018 Scipreneur Private Limited 0

Diabetes drug “significantly reverses memory loss” in mice with Alzheimer’s By: Lancaster University News The research, published in Brain Research, could bring substantial improvements in the treatment of Alzheimer’s disease through the use of a drug originally created to treat type 2 diabetes. Lead researcher Professor Christian Holscher of Lancaster University in [..]